Striving to develop
new therapies for neuroscience diseases
We are focused on providing improved treatments for devastating and life-threatening neuroscience diseases that affect millions of people worldwide. Even the most frequently diagnosed neuroscience diseases often lack adequate treatment options, many of which do not provide meaningful efficacy, pose challenges with adherence, or are associated with unwanted side effects. Addressing these underserved needs and patient communities is the focus of our research and development efforts.
Our approach to developing our therapeutic candidates is predicated on highly specific solutions to the challenges of treating neuroscience diseases that the pharmaceutical industry has attempted to address for years.
Our scientific strategy
Unlocking new treatment opportunities by understanding the neurocircuitry underlying the manifestation of symptoms
Achieving optimal therapeutic benefit and minimizing unintended side effects in neuroscience diseases requires tuning the specificity and dynamic range of neural networks. Recent advancements in chemistry, genomics and proteomics have provided tools to enable a better understanding of the neural networks that underlie these diseases. Fine-tuning the dynamic range requires carefully-designed receptor pharmacology, such as allosteric modulation, to normalize neural network function without over-activation or over-suppression.
Our pipeline
Advancing a broad and diverse neuroscience pipeline
We are advancing a broad and diverse pipeline of small molecule therapies to address significant unmet medical needs and limited treatment options for patients suffering from some of the most devastating neuroscience diseases.
Our pipeline is comprised of multiple preclinical and clinical-stage therapeutic candidates that have the potential to achieve optimal therapeutic activity while minimizing the unintended side effects of currently available therapies.
| Compound | Disease Area | Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Mechanism |
|---|---|---|---|---|---|---|---|
|
Schizophrenia |
M4 PAM |
||||||
|
Alzheimer’s Disease Psychosis |
Fast Track Designation |
M4 PAM |
|||||
|
Epilepsy |
GABAA a2/3/5 PAM |
||||||
|
Panic Disorder |
GABAA a2/3/5 PAM |
||||||
|
Monotherapy (Early-Stage) Parkinson’s |
D1/D5 Strong Partial Agonist |
||||||
|
(adjunct with L-dopa) |
Adjunctive (Late-Stage) Parkinson’s |
D1/D5 Strong Partial Agonist |
|||||
|
Dementia-Related Apathy |
Fast Track Designation |
D1/D5 Partial Agonist |
|||||
|
CVL-354 |
MDD / Substance Use Disorder |
KOR Antagonist |
|||||
|
PDE4 Inhibitor |
Psychiatric, Neuroinflammatory & Other Disorders |
PDE4 Inhibitor |
|||||
|
M4 Agonist |
Psychiatric & Neurological Indications |
M4 Agonist |
|||||